Agios Pharmaceuticals, Inc. (AGIO)

Market Cap	2.58B
Revenue (ttm)	31.31M
Net Income (ttm)	-364.93M
Shares Out	56.89M
EPS (ttm)	-6.49
PE Ratio	n/a
Forward PE	10.51
Dividend	n/a
Ex-Dividend Date	n/a

Volume	340,092
Open	45.31
Previous Close	45.66
Day's Range	44.75 - 45.75
52-Week Range	19.80 - 53.29
Beta	0.75
Analysts	Buy
Price Target	52.00 (+14.59%)
Earnings Date	Oct 31, 2024

About AGIO

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 2013
• Employees: 386
• Stock Exchange: NASDAQ
• Ticker Symbol: AGIO
• Website: https://www.agios.com

Financial Performance

In 2023, Agios Pharmaceuticals's revenue was $26.82 million, an increase of 88.36% compared to the previous year's $14.24 million. Losses were -$352.09 million, 51.9% more than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is $52.0, which is an increase of 14.59% from the latest price.

Price Target

$52.0

(14.59% upside)

Analyst Consensus: Buy